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Despite improvement in morbidity and mortality with cardiac resynchronization therapy
(CRT), disease progression continues to affect a subset of patients and there is limited effort
to identify contributing factors. Our objective was to investigate if a protocol-driven
approach incorporated in a management strategy of heart failure immediately after im-
plantation would provide incremental benefits beyond usual care after implantation. We
reviewed 114 consecutive patients with CRT implanted from 2005 through 2009 who
received usual care after implantation or underwent protocol-driven CRT care after
implantation. Preimplantation characteristics in patients receiving usual versus protocol-
driven care were similar in left ventricular (LV) dimension (LV internal diastolic diameter
6.2  0.8 vs 6.4  1.0 cm), LV ejection fraction (26  8% vs 25%  8%), QRS width, and
medication usage. Major adjustments during the protocol-driven approach were uptitration
of neurohormonal blockers (64%), echocardiographically guided atrioventricular optimi-
zation (50%), heart failure education (42%), arrhythmia management (19%), and LV lead
repositioning (7%). Although positive LV remodeling was noted in the 2 groups at 6
months, extent was significantly greater in the protocol-driven approach compared to usual
care (change in LV internal diastolic diameter 0.7  0.6 cm vs 0.2  1.2 cm, p  0.01;
change in LV ejection fraction 11  7% vs 7  9%, p  0.01), which was associated with
fewer major adverse events (14% vs 53%, p <0.001). In conclusion, a protocol-driven
approach for patients with CRT started immediately after implantation is associated with
incremental favorable effects on reverse remodeling and fewer adverse events compared to
usual care after implantation. These effects appeared to be driven not only by changes in
device settings and arrhythmia management but also by concomitant medication optimi-
zation and heart failure education. © 2011 Elsevier Inc. All rights reserved. (Am J
Cardiol 2011;108:409–415)
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dMost therapeutic effects of cardiac resynchronization
therapy (CRT) have been attributed to device-induced de-
crease in dyssynchrony. For those who do not demonstrate
noticeable improvements immediately after implantation,
further optimization of specific device programming, ar-
rhythmia management, and considerations for lead reposi-
tioning, if suboptimal, can be beneficial.1 However, it is
ften assumed that only those who did not respond over
ime would benefit from such optimization strategies be-
ause the maximal therapeutic effect of CRT should be
erived if implantation and device programming are opti-
al. Factors favorably or adversely affecting CRT efficacy,
articularly those in the immediate postimplantation setting,
ave not been extensively studied. Therefore, the objective
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oi:10.1016/j.amjcard.2011.03.060f this study was to investigate if a protocol-driven ap-
roach incorporated in a management strategy of heart fail-
re immediately after implantation would provide incre-
ental benefits beyond usual care after implantation
ncluding changes in exercise and echocardiographic pa-
ameters and long-term adverse cardiac events.
ethods
This study included consecutive patients with CRT using
n implanted pacemaker or defibrillator under standard clin-
cal indications in a single tertiary cardiac care institution
rom November 2005 through February 2010. All patients
emonstrated stable but advanced heart failure symptoms
New York Heart Association functional class III or IV
ymptoms) despite receiving optimal medical therapy as
olerated by the patient, decreased left ventricular (LV)
jection fraction (35%), and prolonged QRS duration
120 ms) at time of implantation. Because of stringent
eimbursement criteria in Belgium, CRT using implanted
efibrillators was performed only cases of previous episodes
f sustained ventricular tachycardia or inducible ventricular
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w
f
D
m
t
t
w
ting us
410 The American Journal of Cardiology (www.ajconline.org)arrhythmia. The study complied with the Declaration of
Helsinki, the locally appointed ethics committee approved
the research protocol, and informed consent was obtained
from the subjects.
A protocol-driven CRT optimization protocol was estab-
lished in August 2008; thus patients were stratified in 2
groups according to CRT implantation before August 2008
(“usual care”) versus after August 2008 (“CRT optimization
protocol”). Before August 2008 patients received usual care
after implantation performed generally by different hospital
staffs. In this model, an electrophysiology nurse performed
a standard device check. Afterward a patient was seen by a
treating cardiologist to assess the patient’s current health
status and symptoms, often also performing echocardiogra-
phy (Figure 1). Changes in device settings and heart failure
therapy were at the discretion of the treating cardiologist.
A postimplantation stepwise CRT optimization protocol
was established as part of a multidisciplinary approach
toward postimplantation CRT care incorporated in manage-
ment program of heart failure in August 2008. In the CRT
optimization protocol, number of scheduled clinic visits was
similar to that of the usual-care group (6 weeks, 3 and 6
months after implantation). Beyond the standard device
check, a more thorough CRT optimization clinic protocol
was conducted, which included a wider variety of measure-
ments and prespecified optimization guidelines performed
in a designated clinic staffed with physicians and nurses
with a broad interest in heart failure and cardiac devices as
previously described (Figure 2).1 In summary, a heart fail-
ure nurse recorded an electrocardiogram to assess heart rate,
QRS width, and AV/PR intervals. This was performed 2
times with the implanted pacemaker turned on and off to
ensure adequate biventricular pacing. Next, an anterior–
posterior and lateral chest x-ray was carried out to deter-
mine optimal positioning of the right atrial, right ventricu-
lar, and LV leads (in basal or midlateral and posterior
position). In the meantime, routine laboratory tests were
done to detect occult hematologic and metabolic derange-
ments. After these measurements, the designated cardiolo-
gist recorded a detailed history on heart failure symptoms,
occurrence of arrhythmias, and potential device-related is-
sues, checked for compliance to medication usage and salt/
fluid restriction, and completed a full physical cardiovascu-
Figure 1. Flow chart presenlar examination.Afterward a comprehensive 2-dimensional echocardio-
graphic examination was performed (Philips Medical Sys-
tems, Andover, Massachusetts) with nominal settings of the
CRT device. All reported echocardiographic measurements
including LV size/function and mitral regurgitation were
averaged from 3 consecutive cycles as recommended by
the American Society of Echocardiography.2 Then an effort
as made to optimize LV diastolic filling when it differed
rom stage I by altering AV timing using conventional
oppler echocardiography. Optimal AV interval was deter-
ined by sampling mitral inflow with pulse-wave Doppler
o correspond with the shortest AV interval that dissociated
he E and A waves but did not interrupt the end of the A
ave.3–5
To evaluate a patient’s physical fitness and ensure biven-
tricular pacing was persistent even during exercise, a cyc-
loergometric bicycle test with maximum oxygen uptake
recording was performed. Based on the findings, a recom-
mendation was proposed to the patient to maximize the
potential of CRT. These recommendations were not mutu-
ally exclusive because actions could be categorized by re-
positioning of the LV lead to correct inappropriate lead
positioning, changes in device programming for suboptimal
device programming (mostly AV timing), or treatment of
arrhythmias medically or invasively.
Thorough efforts were taken toward optimization of
medical therapy, i.e., uptitration of neurohormonal blockers
to guideline-recommended doses, which were often not
tolerated before implantation. In addition, adequate heart
failure education was provided to familiarize a patient with
heart failure risk factors and modifications in lifestyle. Patients
were informed through dietary consults about salt-free diets (2
to 3 g/day) and fluid restriction (1 to 1.5 L/day), which often
coincided with a progressive decrease in loop diuretic doses.
Importantly, all these adjustments were implemented in close
collaboration with general practitioners who were informed
through telephone contact the day of the patient’s clinic visit
and provided with the findings and recommendations of the
clinic through an on-line letter sent immediately after the CRT
clinic visit to ensure optimization of medical therapy was
accomplished at home under close supervision.
We prespecified the primary end points for analysis as
time to first occurrence of any of the following: all-cause
ual care after implantation.mortality, cardiac transplantation, and/or first readmission
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411Heart Failure/Protocol-Driven Cardiac Resynchronization Clinicfor heart failure after implantation. Patients in the usual-care
group were followed from implantation to the date of the
first visit to the protocol-driven care clinic, whereas patients
in the protocol-driven group were followed until April 30,
2010.
Collected data are expressed as mean  SD for contin-
uous data and as ratio for categorical data. Paired-sample t
ests were performed for variables between related patient
ata groups and independent-sample t tests were performed
for variables between unrelated patient data groups. Statis-
tical significance was set at a 2-tailed probability level with
alpha equal to 0.05. Kaplan–Meier survival curves were
calculated with combined end points for all patients strati-
fied in 2 groups. Cox proportional hazards regression model
was used to determine which variables were related signif-
icantly to the different end point during the follow-up pe-
riod. The authors had full access to the data and take
responsibility for the integrity of the data. All authors have
read and agreed to the report as written. All statistical
analyses were performed using SPSS 17.0 for Windows
Figure 2. Flow chart presenting protocol-driven postimplantation manag
ptimization; biv.  biventricular; ECG  electrocardiography; ECHO 
diastolic diameter.(SPSS, Inc., Chicago, Illinois). wResults
Preimplantation patient characteristics are presented in
Table 1 and were similar in the 2 groups (n  53 in
sual-care group and 61 in protocol-driven group) including
egree of LV remodeling and maximum exercise capacity.
here was a large and similar proportion of use of neuro-
ormonal blockers. For the CRT optimization group, mean
linic visit duration was 40 minutes with involvement of a
esignated nurse (20 minutes) and a cardiologist (20
inutes).
All patients had a lead implanted in the right atrium, right
entricle, and left ventricle through the coronary sinus
72%) or epicardially (28%). X-rays demonstrated no lead
islodgement but indicated a suboptimal positioning of the
V lead for 8 patients. One patient was scheduled for LV
ead repositioning.
Device interrogation was successful in all patients,
hich was paced mostly in an atrial sensing–ventricu-
ar pacing mode. No battery depletion or lead integrity
in cardiac resynchronization therapy clinic. AV opt.  atrioventricular
cardiography; EF  ejection fraction; LVIDd  left ventricular internalement
echoas noted.
EC
412 The American Journal of Cardiology (www.ajconline.org)Arrhythmias were present in 19% of patients, mostly
atrial fibrillation, but in 7% frequent ventricular ectopy was
present, leading to 100% biventricular pacing in 19% and
90% in 17% of patients. All arrhythmias were treated
accordingly at least to ensure 90% biventricular pacing in
95% instead of 83% of patients.
An additional 50% of patients were found to be pro-
grammed with suboptimal AV timing settings. AV timings
were always optimized in these patients after an improve-
ment in LV filling. These improvements were confirmed
during the next clinic visit, with only 2 patients needing an
additional change in their AV timings.
Uptitration in neurohormonal blockers was possible for
64% of patients, although 90% were already receiving
angiotensin-converting enzyme inhibitor and -blocker
medication at time of implantation. Interestingly, all these
patients were already taking a similar dosage of neurohor-
Table 1
Baseline demographics
Demographics
Age (years)
Men
Cardiac resynchronization therapy with defibrillator
Weight (kg)
Body mass index (kg/m2)
25
30
Hypertension (140/90 mm Hg)
Hyperlipidemia (low-density lipoprotein 110 mg/dl)
Quit smoking
Active smoking
Diabetes mellitus
Atrial fibrillation
Medications
Aspirin
Angiotensin-converting enzyme inhibitors and angiotensin receptor bloc
 Blockers
Spironolactone
Loop diuretic
Statin
Hydralazine
Isosorbide dinitrate
Digoxin
lectrocardiographic data
Heart rate (beat/min)
PR width (ms)
QRS width (ms)
ycloergometric data
Maximum exercise capacity (watts)
Systolic/diastolic blood pressure at rest (mm Hg)
Systolic/diastolic blood pressure during exercise (mm Hg)
Maximum heart rate (beats/min)
Maximum volume (ml/kg/min)
Echocardiographic data
Left ventricular internal diastolic diameter (cm)
Left ventricular ejection fraction (%)
Mitral valve regurgitation (grade II)
Tricuspid valve regurgitation (grade II)monal blockers for 3 months before device implantationand only noted an improved tolerance toward uptitration of
these drugs after implantation (Figure 3).
Failure in patient compliance with regard to salt/water
restriction and stringent intake of medication was high be-
cause 42% patients testified to having poorly followed their
daily medication intake and dietary advice. After implemen-
tation of heart failure education and dietary consult, in
collaboration with general practitioners 22% of patients had
a decrease in dosage of loop diuretic (Figure 4).
In addition, 63% patients were obese, 13% of patients
had anemia, but only 1 patient had hemoglobin 10 g/dl,
which was treated with transfusion or erythropoietin agents.
Starting from August 2008 all patients receiving usual
care were also referred to the protocol-driven CRT clinic.
Interestingly, clinical, electrophysiologic, and device-re-
lated interventions were similar overall compared to pa-
tients followed in the protocol-driven clinic immediately
Total Usual Care Protocol-Driven p Value
(n  114) (n  51) (n  63)
71  10 72  10 71  11 NS
64% 55% 73% 0.04
51% 52% 48% NS
77  17 76  16 79  17 NS
28  5 27  5 28 5 NS
73% 70% 76% NS
33% 30% 36% NS
42% 40% 43% NS
33% 28% 37% NS
20% 21% 18% NS
10% 12% 9% NS
30% 30% 30% NS
42% 38% 44% NS
76% 76% 75% NS
88% 84% 90% NS
89% 82% 94% NS
58% 39% 73% 0.001
75% 84% 67% 0.02
59% 55% 62% NS
9% 2% 14% 0.02
6% 2% 10% NS
24% 24% 24% NS
72  21 75  19 70  22 NS
192  47 192  48 191  44 NS
159  31 155  31 160  31 NS
89  32 84  22 90  34 NS
126/74 115/71 127/74 NS
151/74 145/67 153/75 NS
112  23 113  18 112  25 NS
13.9  4.6 12.4  3.2 13.9  4.7 NS
6.3  1 6.2  0.8 6.4  1 NS
25  8 26  8 25  8 NS
10% 11% 10% NS
3% 2% 3% NSkersafter implantation. Indeed, uptitration of neurohormonal
413Heart Failure/Protocol-Driven Cardiac Resynchronization Clinicdrugs was possible for 1/2 the patient population, decrease
in dosage of loop diuretics for 20% of patients, and 43% of
patients confirmed to having poorly maintained their med-
ication and dietary guidelines. In addition, 51% of patients
were shown to be paced with suboptimal AV timings and
20% of patients presented with arrhythmias.
Positive remodeling was noted in the 2 groups with regard
to LV dimension and LV function. However, extent of positive
LV remodeling and improvement in LV ejection fraction were
significantly greater in the group receiving a protocol-driven
approach from the start (Figure 5). Moreover, as presented in
Table 2, improvement in maximum exercise capacity as mea-
sured through maximum oxygen consumption was more pro-
nounced for the protocol-driven group. Interestingly, these
positive effects did not seem to relate to a greater decrease in
dyssynchrony because the decrease in QRS and PR times did
not differ between groups.
At the end of the follow-up period (mean follow-up dura-
Figure 3. Interventions performed during visit to protocol-driven optimiza
suboptimal. Other abbreviations as in Figure 2.
Figure 4. Bar graph presenting percentage of patients whose medication
was optimized in the protocol-drive optimization cardiac resynchronization
therapy clinic. Ace  angiotensin-converting enzyme.tion 19  11 months for the 2 groups), 36% of patients haddied, undergone cardiac transplantation, and/or were hospital-
ized for decompensated heart failure. Although overall mor-
tality/cardiac transplantation was similar for the 2 groups (3 vs
rdiac resynchronization therapy clinic. RV  right ventricular; Subopt 
Figure 5. Bar graph for left ventricular internal diameter in diastole (cen-
timeters) and left ventricular ejection fraction (percentage) at time of
implantation versus follow-up for the 2 study groups. Abbreviations as in
Figure 2.tion ca4 events, p  1), patients receiving protocol-driven care had
tD
a
z
r
r
s
t
o
m
f
c
b
b
t
t
i
p
m
p
t
o
n
a
a
a
t
d
a
i
a
i
a
r
d
d
m
(
(
t
c
t
H
p
m
i
f
t
i
C
e
v
c
b
414 The American Journal of Cardiology (www.ajconline.org)fewer adverse events during follow-up (28 vs 9 events, p
0.001; Figure 6). The protocol-driven follow-up was not
associated with lower all-cause mortality (odds ratio 1.085,
95% confidence interval 0.231 to 5.084, p  NS) but did lead
to a decrease in heart failure hospitalization (odds ratio 0.137,
95% confidence interval 0.056 to 0.335, p 0.001) compared
o routine care after implantation.
iscussion
The potential benefit of heart failure management in
ddition to a comprehensive protocol-driven CRT optimi-
ation strategy has been demonstrated in patients without
obust clinical or echocardiographic responses to CRT.1 We
eport for the first time a potential incremental benefit of
uch a CRT optimization strategy immediately after implan-
ation of CRT, which is in part driven not only by device
ptimization but also by judicious uptitration of neurohor-
onal blockers and decreases in loop diuretics and heart
ailure education in close coordination of care with primary
aregivers.
As in other interventions, extent of response to CRT can
e heterogenous, and there is ongoing debate regarding the
est strategies to optimize device performance. Much atten-
ion has focused primarily on refining preimplantation pa-
ient selection to predict a favorable response or on improv-
ng techniques and determination of optimal lead
ositioning to achieve maximal synchronization. However,
aximizing benefits of CRT for those with implants is
articularly important because CRT is an invasive interven-
ion with known complications. Our group previously dem-
Table 2
Clinical data
Time of
Implantation
Follow-Up p Value
Echocardiographic data
Left ventricular internal diastolic
diameter (cm)
Usual care 6.2  0.8 6.0  1.0 0.05
Protocol-driven care 6.4  1.0 5.8  0.9 0.001
Left ventricular ejection fraction
(%)*
Usual care 26  8 33 9 0.001
Protocol-driven care 25  8 37 9 0.001
Cycloergometric data
Maximum volume (ml/kg/min)*
Usual care 14.1  3.2 14.5  2.5 NS
Protocol-driven care 14.0  4.8 15.5  4.2 0.03
Maximum heart rate (beats/min)
Usual care 117  18 104  22 NS
Protocol-driven care 115  24 105  26 0.02
Electrocardiographic data
PR width (ms)
Usual care 187  45 142  26 0.001
Protocol-driven care 188  46 128  30 0.001
QRS width (ms)
Usual care 155  32 149  30 NS
Protocol-driven care 157  29 150  21 NS
* There was a significant difference between the 2 study groups at
follow-up.nstrated in a systematic evaluation of implementation thatonresponding patients in a large subset of patients
chieved substantial benefit by a combination of device
djustments and standard components of heart failure man-
gement interventions.1 We extend our findings to all pa-
ients immediately after CRT implantation in which imme-
iate assessment of device parameters guided by clinical
nd echocardiographic evaluation may be associated with
ncremental clinical and echocardiographic responses that
re directly associated with better long-term outcomes. Sim-
lar to our previous findings in the nonresponder population,
large majority of issues identified included presence of
hythm abnormalities (19%) with concomitant inadequate
elivery of biventricular pacing, improving compliance in
ecreasing salt and fluid intakes (42%), optimization of
edical management as an adjunct to device adjustments
64%), and echocardiographically guided AV-optimization
50%). These observations were unlikely biased by selec-
ion because the indication, implantation, and postprocedure
are were provided by the same personnel with the excep-
ion of the additional upfront protocol-driven evaluation.
ence, our observations highlight the notion that current
ostimplantation approaches to longitudinal monitoring
ay overlook important issues such as optimization of med-
cal therapy and heart failure education.
One of the most intriguing findings in our report is that
or the first time we observed that up to 2/3 of patients
olerated uptitration of neurohormonal blockers after CRT
mplantation to dosages previously not tolerated before
RT implantation. There may be several reasons that may
xplain this observation. First, the ability for CRT to pro-
ide hemodynamic augmentation in the setting of dyssyn-
hrony has been well described in the literature and has
een the basis for its indication.1,6,7 Second, the dependency
of diuretic therapy to relieve congestion may be decreased;
hence, adjustments of diuretic therapy may be necessary to
better optimize the filling pressures needed to promote re-
covery. The 2 effects can commence immediately after CRT
and perhaps more promptly after better adjustments of atrio-
ventricular delay to establish the most optimal mitral inflow
pattern. The ability to increase transition of care from time
of discharge after device implantation to long-term manage-
ment of heart failure likely further facilitates long-term
improvement.
The design of our protocol-driven follow-up of ambula-
tory patients implanted with a CRT is unique yet scalable to
broad adoption. First, it commenced immediately after im-
plantation in all patients with implanted CRT, thus provid-
ing an upfront assessment and intervention that may benefit
a larger proportion of patients especially when applied even
at the time of discharge from hospitalization for implanta-
tion. Second, it used a combination of readily applicable
(rather than research-based) testing and interventions that is
familiar to patients and health care providers in a manner
similar to our approach in the nonresponder population.1
Although positive effects toward improvement in exer-
cise capacity and remodeling were noticeable in the 2
groups, the extent of these positive effects was significantly
greater with the protocol-driven approach, ultimately lead-
ing to a decreased incidence of adverse events at follow-up.
Interestingly, this was not attributable to a more pronounced
decrease in electrical dyssynchrony in the protocol-driven
415Heart Failure/Protocol-Driven Cardiac Resynchronization Clinicapproach. It is therefore conceivable that nondevice-related
contributors of CRT response that can act independently of
(but synergistically to) cardiac resynchronization will di-
rectly influence clinical and echocardiographic responses to
CRT. Because contemporary postimplantation patient man-
agement is evolving more and more toward remote evalu-
ation and monitoring, our data may argue conversely that an
improvement in clinical or echocardiographic response after
successful resynchronization should not imply that a routine
follow-up visit or just a remote device follow-up is suffi-
cient. Instead, it is conceivable that an upfront comprehen-
sive heart failure management approach is warranted in
patients receiving CRT to ensure a more persistent and
meaningful alteration in the natural history of heart failure,
thus maximizing chances to delay disease progression.
It is important to recognize that this is a single-center
experience and not a randomized but a historical control com-
parison of 2 treatment strategies. Nevertheless, the period was
selected because implantation indications and techniques were
relatively mature and care patterns delivered by health care
providers (including indications for medical and device thera-
Figure 6. Kaplan–Meier survival curve for clinical outcomes of usual car
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